Following World War I and in light of growing international pharmaceutical trade and the League of Nations' emerging role in public health, a revised treaty was negotiated in 1925. This second conference met in Brussels'
Academy Palace from 10 to 29 September 1925, resulting in a revised international agreement. This version, agreed upon at a conference in Brussels with broader international participation, expanded the harmonized list to 77 items (including
cannabis and
digitalis), introduced
dosage standards, and established a provisional "Permanent International Pharmacopoeia Secretariat". The countries that signed in 1925 were
Austria,
Belgium,
Bulgaria,
Denmark,
Finland,
France,
Germany,
Greece,
Hungary,
Ireland,
Italy,
Latvia,
Luxembourg,
Netherlands,
Norway,
Poland,
Romania,
Spain,
Sweden,
Switzerland,
Turkey,
UK, and
Yugoslavia. The treaty entered into force in 1929. Despite not explicitly referring to an "international pharmacopoeia", the treaty allowed for harmonized national monographs to bear the abbreviation "P. I." (for
protocole international), which was often misread as
Pharmacopoeia Internationalis. The German pharmacopoeia
DAB 6 interpreted it as
Præscripcio Internationalis (international prescription). While uptake of the 1925 formulae was greater than the 1906 version, both agreements ultimately fell short of fully standardizing pharmaceutical texts across countries. Much more countries included harmonizes monographs in their national pharmacopoeias, but they often cherry-picked which monographs to harmonize. == Treaty provisions ==